Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 840 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Doctors Seem To Be Biased Against Unmarried Cancer Patients, Offer Them... November 26, 2019 Radionuclide Therapy Could Be A Viable Treatment For Early-Stage Breast Cancer,... February 20, 2020 Rediscovered Drugs Hit Leukemia from Two Different Angles July 21, 2020 No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk... June 22, 2026 Load more HOT NEWS Popular Fitness Instructor Encourages Others to Maintain Routine Check Ups After... BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions Moving target – retrotransposable elements and cancer Coming together for Zynlonta
